Analysts Picks & Changes

Analysts Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 9/25 cls
Biogen Idec Inc. (NASDAQ:BIIB) UBS Maged Shenouda Price target Neutral 0% $50.11
Shenouda raised his target to $56 from $54 after the U.S. Patent and Trademark Office issued Biogen Idec a new patent covering the use of beta interferon for immunomodulation, which the company said covers its Avonex interferon beta-1a and extends its patent to 2026 from 2013. Avonex is approved to treat multiple sclerosis (MS).
Celgene Corp. (NASDAQ:CELG) Baird Christopher Raymond

Read the full 1026 word article

How to gain access

Continue reading with a
two-week free trial.